These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 36951997)

  • 1. A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022.
    Kayki-Mutlu G; Aksoyalp ZS; Wojnowski L; Michel MC
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Aug; 396(8):1619-1632. PubMed ID: 36951997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023.
    Kayki-Mutlu G; Aksoyalp ZS; Wojnowski L; Michel MC
    Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):2949-2970. PubMed ID: 38530400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021.
    Kayki-Mutlu G; Aksoyalp ZS; Wojnowski L; Michel MC
    Naunyn Schmiedebergs Arch Pharmacol; 2022 Aug; 395(8):867-885. PubMed ID: 35543739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020.
    Kayki-Mutlu G; Michel MC
    Naunyn Schmiedebergs Arch Pharmacol; 2021 May; 394(5):839-852. PubMed ID: 33864098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Pharmaceutical Industry in 2023: An Analysis of FDA Drug Approvals from the Perspective of Molecules.
    de la Torre BG; Albericio F
    Molecules; 2024 Jan; 29(3):. PubMed ID: 38338330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017.
    Zhang AD; Puthumana J; Downing NS; Shah ND; Krumholz HM; Ross JS
    JAMA Netw Open; 2020 Apr; 3(4):e203284. PubMed ID: 32315070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of US Food and Drug Administration new drug and biologic approvals, regulatory pathways, and review times, 1980-2022.
    Seoane-Vazquez E; Rodriguez-Monguio R; Powers JH
    Sci Rep; 2024 Feb; 14(1):3325. PubMed ID: 38336899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
    Darrow JJ; Avorn J; Kesselheim AS
    JAMA; 2020 Jan; 323(2):164-176. PubMed ID: 31935033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Pharmaceutical Industry in 2022: An Analysis of FDA Drug Approvals from the Perspective of Molecules.
    de la Torre BG; Albericio F
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action.
    Olivier T; Haslam A; Prasad V
    JAMA Netw Open; 2021 Dec; 4(12):e2138793. PubMed ID: 34905002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of US Food and Drug Administration Expedited Drug Development and Review Programs by Orphan and Nonorphan Novel Drugs Approved From 2008 to 2021.
    Monge AN; Sigelman DW; Temple RJ; Chahal HS
    JAMA Netw Open; 2022 Nov; 5(11):e2239336. PubMed ID: 36318210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. US Food and Drug Administration Review Time of Supplemental New Indication Approvals of Drugs and Biologics, 2017 to 2019.
    Dhodapkar MM; Ross JS; Ramachandran R
    JAMA Netw Open; 2023 Jun; 6(6):e2318889. PubMed ID: 37358857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approvals and Timing of New Formulations of Novel Drugs Approved by the US Food and Drug Administration Between 1995 and 2010 and Followed Through 2021.
    Gupta R; Morten CJ; Zhu AY; Ramachandran R; Shah ND; Ross JS
    JAMA Health Forum; 2022 May; 3(5):e221096. PubMed ID: 35977259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019.
    Dhodapkar M; Zhang AD; Puthumana J; Downing NS; Shah ND; Ross JS
    JAMA Netw Open; 2021 Jun; 4(6):e2113224. PubMed ID: 34110392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. US-FDA Approved Drugs in 2020 and 2021: A Review.
    Passi I; Salwan S; Kumar B
    Mini Rev Med Chem; 2023; 23(12):1273-1297. PubMed ID: 36503454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules.
    G de la Torre B; Albericio F
    Molecules; 2019 Feb; 24(4):. PubMed ID: 30813407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Drugs Approved in 2022.
    Ebied AM; Elmariah H; Cooper-DeHoff RM
    Am J Med; 2023 Jun; 136(6):545-550. PubMed ID: 36889492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Drugs Approved in 2021.
    Ebied AM; Elmariah H; Cooper-DeHoff RM
    Am J Med; 2022 Jul; 135(7):836-839. PubMed ID: 35235820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.